Web Exclusives

Data Analysis Shows 8-week Chemoradiotherapy-to-Surgery Timeline Achieves Optimal Tumor Response

Overall survival was best and resection of residual locally advanced rectal tumors most successful when surgery occurred at precisely 8 weeks, or 56 days, after completion of chemoradiotherapy.

Nanoparticle System Uses Light Waves to Target Release Site of Drug

Nanoparticles that release a drug only when exposed to near-infrared (NIR) light are a promising drug-delivery agent developed by Canadian researchers.

Delirium is Common in Older Patients Undergoing GI Surgery

Older patients undergoing gastrointestinal surgery often experience postoperative delirium. In an analysis of 11 studies, incidence of postoperative delirium ranged from 8.2% to 54.4%.

Nanoparticle Drug Delivery Aims to Control Pancreatic Tumor and Inhibit Escape Pathways

Use of a nanoparticle to deliver drugs may reduce tumors and suppress metastatic escape. These efforts offer a way to control drug release over space and time while reducing systemic drug exposure and the associated side effects.

CDX2 Expression Predictive of Chemotherapy Benefit in Patients With Stage II Colorectal Cancer

Lack of CDX2 expression identified a subgroup of patients with high-risk stage II colon cancer who seemed to benefit from adjuvant chemotherapy.

Development of Microtubulin Inhibitor Is a Potential Lead to Novel Biologic Therapy

Gatastatin, an inhibitor specific for γ-tubulin, known to be overexpressed in some cancer cells, has been identified and holds potential for the development of anticancer agents.

Proposed Regimen for Ovarian Cancer Is Aggressive, But Could Achieve a 50% Cure Rate

Combining a maximal debulking strategy and intraperitoneal chemotherapy could maximize the chance of achieving a cancer-free state, as explained in a recent clinical perspective piece.

Targeted Hormone-radiation Treatment Shows Promise in Midgut Neuroendocrine Tumors

Tumor growth may be substantially slowed by the novel therapy 177Lutetium-DOTATATE (Lutathera), according to early results from a phase III study of patients with previously treated, advanced midgut neuroendocrine tumors.

Inherited Genetic Markers Predictive of Survival Prognosis for Patients with Melanoma

Prognosis for patients with cutaneous melanoma may be predicted by an inherited genetic marker providing a personalized tool to gauge a person's survival and determine if closer monitoring is needed in the years following surgery.

CDK4/6 Inhibitors Exploit a Unique Vulnerability in Pancreatic Cancer

CDK4/6 Inhibitors Exploit a Unique Vulnerability in Pancreatic Cancer

The metabolism of pancreatic cancer cells is altered by the anticancer activity of CDK4/6 inhibitors. Researchers hope this biologic vulnerability could be exploited to treat pancreatic cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs